That’s an interesting question. There’s going to be a number of changes, right? In the UK, we are on the cusp of NICE approvals, hopefully, of these combination therapies. So we’ve, you know, Tafa R-squared and Epcor R-squared are both going through. We’ve recently had epcoritamab approved. So we’re definitely seeing bispecific antibodies being part of the treatment landscape for relapse disease...
That’s an interesting question. There’s going to be a number of changes, right? In the UK, we are on the cusp of NICE approvals, hopefully, of these combination therapies. So we’ve, you know, Tafa R-squared and Epcor R-squared are both going through. We’ve recently had epcoritamab approved. So we’re definitely seeing bispecific antibodies being part of the treatment landscape for relapse disease. The trials are obviously moving those bispecs into first line and the anticipation is that they will show some superiority over standard immunochemotherapy and I think that’s then going to create the biggest challenge of trying to select patients who might require these therapies because at moment, one of the challenges we’ve got in follicular lymphoma is we can’t predict individual patient risk at baseline. So our prognostic biomarkers are completely useless in terms of predicting individual risk or treatment benefit. So we face a situation where we’re going to have many more therapies, and we haven’t even talked about CAR-T, but we’re going to have many more therapies on the treatment landscape and our real challenge is going to be how do we select them, when do we select them, how do we sequence those patients or those therapies but we will definitely have more treatments hopefully available to inform that decision.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.